Background-Pharmacological interventions for prevention of sudden arrhythmic death in patients with chronic heart failure remain limited. Accumulating evidence suggests increased ventricular expression of T-type Ca 2ϩ channels contributes to the progression of heart failure. The ability of T-type Ca 2ϩ channel blockade to prevent lethal arrhythmias associated with heart failure has never been tested, however. Methods and Results-We compared the effects of efonidipine and mibefradil, dual T-and L-type Ca 2ϩ channel blockers, with those of nitrendipine, a selective L-type Ca 2ϩ channel blocker, on survival and arrhythmogenicity in a cardiac-specific, dominant-negative form of neuron-restrictive silencer factor transgenic mice (dnNRSF-Tg), which is a useful mouse model of dilated cardiomyopathy leading to sudden death. Efonidipine, but not nitrendipine, substantially improved survival among dnNRSF-Tg mice. Arrhythmogenicity was dramatically reduced in dnNRSF-Tg mice treated with efonidipine or mibefradil. Efonidipine acted by reversing depolarization of the resting membrane potential otherwise seen in ventricular myocytes from dnNRSF-Tg mice and by correcting cardiac autonomic nervous system imbalance. Moreover, the R(Ϫ)-isomer of efonidipine, a recently identified, highly selective T-type Ca 2ϩ channel blocker, similarly improved survival among dnNRSF-Tg mice. Efonidipine also reduced the incidence of sudden death and arrhythmogenicity in mice with acute myocardial infarction. Key Words: ion channels Ⅲ nervous system, autonomic Ⅲ heart failure Ⅲ calcium Ⅲ arrhythmia A s many as 50% of deaths among heart failure patients are sudden and unexpected, presumably the result of lethal arrhythmias. 1 Despite recent progress in nonpharmacological therapy, pharmacological interventions for the treatment and prevention of lethal arrhythmias associated with chronic heart failure remain limited. A prerequisite for the development of new pharmacological approaches is to identify potential targets based on knowledge of the molecular basis of arrhythmogenesis in failing hearts.
Conclusions-T-type
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Compelling evidence implicates T-type Ca 2ϩ channels in the progression of heart failure. 2, 3 During development, T-type Ca 2ϩ channels are abundantly expressed in the embryonic ventricle, but their expression is suppressed in the adult ventricle, so that it is restricted to the conduction system. 4, 5 However, T-type Ca 2ϩ channels are reexpressed in hypertrophied and failing ventricles, 4,6 -9 and the resultant T-type Ca 2ϩ currents (I Ca,T ) are thought to be involved in the pathological process that leads to systolic dysfunction and arrhythmogenesis. 2, 9 Indeed, several studies have shown that mibefradil, which blocks both T-and L-type Ca 2ϩ channels, mitigates the functional deterioration of the ventricle in some animal models of heart failure. 10 -12 More recently, it was shown that the genetic deletion of CACNA1H, which encodes the ␣1H T-type Ca 2ϩ channel, resulted in resistance to pathological cardiac hypertrophy. 9 The ability of T-type Ca 2ϩ channel blockade to prevent malignant arrhythmia and sudden death associated with heart failure remains unevaluated, however.
We recently reported that a transcriptional repressor, neuron-restrictive silencer factor (NRSF, also called REST), is an important regulator of the fetal cardiac gene program. 13 Transgenic mice that selectively express a dominant-negative form of NRSF (dnNRSF) in their hearts (dnNRSF-Tg) showed progressive cardiomyopathy and sudden arrhythmic death beginning at Ϸ8 weeks of age. 14 The dnNRSF-Tg hearts showed increased expression of fetal-type ion channel genes, including CACNA1H, which encodes the T-type Ca 2ϩ channel ␣-subunit. Moreover, I Ca,T amplitude was correspondingly increased in ventricular myocytes from dnNRSF-Tg hearts, which suggests that I Ca,T in some way contributes to the susceptibility of dnNRSF-Tg hearts to arrhythmias. 14 To clarify the contribution made by T-type Ca 2ϩ channels to the development of malignant arrhythmias and to assess the ability of T-type Ca 2ϩ channel blockade to prevent sudden death associated with heart failure, we compared the effects of efonidipine and mibefradil, dual T-and L-type Ca 2ϩ channel blockers, 15, 16 with those of nitrendipine, a more L-type-selective Ca 2ϩ channel blocker, on survival and arrhythmogenicity in dnNRSF-Tg mice and mice with myocardial infarction. We also tested the effects of the R(Ϫ)-isomer of efonidipine [R(Ϫ)-efonidipine], a recently identified, highly selective T-type Ca 2ϩ channel blocker, on dnNRSF-Tg mice. 17, 18 Our findings demonstrate that T-type Ca 2ϩ channel blockade may represent a new and effective means of preventing sudden cardiac death in patients with heart failure.
Methods
Animal Experiments
Animal care and all experimental protocols were conducted in accordance with the institutional guidelines of the Kyoto University Graduate School of Medicine. Beginning at 8 weeks of age, dnNRSF-Tg mice were left untreated (control) or were treated for 7 weeks with efonidipine (40 mg · kg
In another experiment, 10-or 11-week-old dnNRSF-Tg mice were left untreated (control) or treated for 7 days with mibefradil (15 mg · kg
The doses of mibefradil, efonidipine, and nitrendipine were chosen on the basis of earlier reports and our preliminary studies. 19 -22 In the experiment with R(Ϫ)-efonidipine, dnNRSF-Tg mice were left untreated (control) or were treated for 20 weeks with the R(Ϫ)-isomer efonidipine (200 mg · kg Ϫ1 · d Ϫ1 PO). Acute myocardial infarction was induced in female C57BL/6 mice (age 8 to 12 weeks; weight 19 to 24 g) by ligation of the left coronary artery as described previously. 23 Beginning 1 day after the operation, mice were left untreated (control) or were treated for 30 days with efonidipine hydrochloride (200 mg · kg
). Efonidipine and R(Ϫ)-isomer efonidipine were supplied by Nissan Chemical Industries, Ltd (Tokyo, Japan). Nitrendipine was purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan).
Patch-Clamp Studies
Myocytes were dispersed by a method described previously. 24 To record T-and L-type Ca 2ϩ currents, electrodes were filled with Cs ϩ -rich solution that contained (in mmol/L): 100 CsCl, 50 NMDG, 10 TEA, 5 MgATP, 5 HEPES, and 10 EGTA (pH 7.2 with CsOH). After establishment of the ruptured whole-cell patch configuration in normal Tyrode solution, the bathing solution was switched to Na ϩ -free solution. A stock solution of efonidipine 10 mmol/L in DMSO was diluted to the desired concentration with Na ϩ -free bathing solution (final concentration 10 mol/L).
Intracardiac Electrophysiology
A 1.7F octapolar catheter (CIBer mouse EP, NuMe, Hopkinton, NY) inserted via the jugular vein was used to perform a standard electrophysiological study protocol as described previously. 14, 25 
Statistical Analysis
Data are presented as meanϮSEM. Survival was analyzed by the Kaplan-Meier method with the log-rank test. ANOVA with post hoc Student-Newman-Keuls tests was used for comparisons among groups. Values of PϽ0.05 were considered significant. Repeatedmeasures analyses with linear mixed-effects models were performed with data comprising repeated observations made over time. Data obtained from the 2-way factorial design were analyzed with the 2-way ANOVA. The double-pulse protocol is shown at the top. Na ϩ currents were suppressed by use of Na ϩ -free bathing solution. I Ca,T were elicited at Ϫ50 mV only in dnNRSF mice. B, Currentvoltage relationship for I Ca,T in cardiomyocytes from dnNRSF mice (nϭ5). At membrane potentials more positive than Ϫ40 mV, peak amplitudes of inward currents elicited from a conditioning potential of Ϫ90 or Ϫ50 mV were subtracted. C, Current-voltage relationship for I Ca,L in cardiomyocytes from dnNRSF mice. The conditioning potential was Ϫ50 mV (nϭ5). D, Effect of efonidipine (Efo) 10 mol/L on I Ca,T (T) and I Ca,L (L). In the top panel, I Ca,T was activated by depolarization to Ϫ45 mV from a holding potential of Ϫ80 mV. Bottom panel, I Ca,L recorded from a myocyte from a WT mouse. I Ca,L was activated by depolarization to Ϫ10 mV from a holding potential of Ϫ80 mV. E, Summary of the inhibitory effects of efonidipine (Efo; 10 mol/L) on I Ca,T (T) and I Ca,L (L) in ventricular myocytes. Efonidipine reduced the amplitudes of I Ca,T by 57Ϯ12% (nϭ4) while reducing the amplitudes of I Ca,L by 21Ϯ4% (nϭ5).
Results
Dual T-and L-Type Ca 2؉ Channel Blocker Efonidipine Improves Survival Among dnNRSF-Tg Mice
We previously showed that dnNRSF-Tg mice develop progressive cardiomyopathy and begin to die of ventricular tachyarrhythmias at Ϸ8 weeks of age. 14 In dnNRSF-Tg hearts, CACNA1H, the gene that encodes the T-type Ca 2ϩ channel ␣-subunit and a transcriptional target of NRSF/ REST, was upregulated, and there was a corresponding increase in I Ca,T amplitude in the isolated ventricular myocytes ( Figure 1A through 1C). 14 By contrast, no I Ca,T were recorded in adult ventricular myocytes from wild-type littermate (WT) hearts ( Figure 1A ). 14 To determine the role played by T-type Ca 2ϩ channels in the development of malignant arrhythmias and sudden death and to assess the potential therapeutic effect of T-type Ca 2ϩ channel blockade in dnNRSF-Tg mice, we administered subpressor doses of efonidipine, a dual T-and L-type dihydropyridine Ca 2ϩ channel blocker, 15, 16 or nitrendipine, a more L-type-selective dihydropyridine Ca 2ϩ channel blocker, to dnNRSF-Tg mice for 7 weeks, beginning when they were 8 weeks of age. Initially, we confirmed that efonidipine significantly blocked I Ca,T in ventricular myocytes from dnNRSF-Tg mice ( Figure 1D and 1E). Consistent with previous reports, efonidipine also blocked I Ca,L in those cells ( Figure 1D and 1E). 15, 16 As shown in Figure 2A , efonidipine dramatically improved the survival rate among dnNRSF-Tg mice compared with mice treated with nitrendipine or control vehicle. We found that heart weight-to-body weight ratios and lung weight-to-body weight ratios did not differ among the control, efonidipine, and nitrendipine groups ( Figure 2B and 2C). In addition, echocardiographic, hemodynamic, and histological analyses showed no significant differences among these 3 groups ( Figure 2D , 2E, and 2F; Table) . Consistent with these findings, there also was no significant difference in the expression of 2 cardiac stress marker genes, BNP and SERCA2, among the 3 groups ( Figure 2G and 2H). 26, 27 Both efonidipine and nitrendipine modestly reduced the increase in CACNA1H expression seen in dnNRSF-Tg hearts ( Figure 2I ), and the expression of CACNA1G did not significantly differ among WT and dnNRSF-Tg mice ( Figure  2J ). These data suggest that efonidipine directly suppresses sudden death in dnNRSF-Tg mice without significantly affecting cardiac structure or function.
Efonidipine Reduces Arrhythmogenicity in dnNRSF-Tg Mice
We next used a telemetric monitoring system to examine the effects of each drug on ECG parameters in dnNRSF-Tg mice. We found that only efonidipine significantly suppressed the 
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number of premature ventricular contractions in dnNRSF-Tg hearts ( Figure 3A ). More importantly, it dramatically reduced the number of episodes of ventricular tachycardia (VT; Figure 3B ). We further assessed the effect of each drug on arrhythmogenicity in dnNRSF-Tg mice by performing an in vivo intracardiac electrophysiological analysis. 14, 25 We found that control dnNRSF-Tg mice were highly susceptible to induction of VT, as reported previously 14 ( Figure 3C and 3D) , and that nitrendipine did not reduce that susceptibility ( Figure  3D ). By contrast, efonidipine significantly reduced the frequency of induced VT ( Figure 3C and 3D) . To confirm that inhibition of T-type Ca 2ϩ currents is responsible for the suppression of arrhythmogenicity in dnNRSF-Tg hearts, we next treated dnNRSF-Tg mice with another dual T-and L-type Ca 2ϩ channel blocker, mibefradil. 28 After 1 week of treatment with mibefradil or efonidipine, dnNRSF-Tg mice showed significantly reduced susceptibility to induced VT ( Figure 3E ).
We next examined the effects of long-term drug treatment on the electrophysiological properties of myocytes isolated from dnNRSF-Tg hearts. When we measured action potentials elicited in isolated ventricular myocytes from WT and dnNRSF-Tg hearts, we found that in the latter, the membrane potential was somewhat depolarized, and the action potential duration was increased ( Figure 3F and 3G) . Efonidipine, but not nitrendipine, significantly restored the resting membrane potential in dnNRSF-Tg myocytes ( Figure 3F and 3G ).
Efonidipine Improves Cardiac Autonomic Nervous System Function in dnNRSF-Tg Mice
A disturbance of autonomic nerve activity that leads to increased sympathetic nerve activity and reduced parasympathetic nerve activity is involved in the increased arrhythmogenicity seen in patients with chronic heart failure. Heart rate variability (HRV) is a widely accepted index of cardiac autonomic nervous system activity. 29 A previous frequencydomain analysis of HRV revealed that patients with severe heart failure show a progressive reduction in power in both the low-frequency and high-frequency ranges. 29, 30 Moreover, the reduction in low-frequency power is a significant predictor of sudden cardiac death in patients with heart failure. 31, 32 T-type Ca 2ϩ channels are normally expressed in neuronal and endocrine tissues, where they play an important role in mediating neurotransmitter release and in the secretion of various neurohumoral factors, including catecholamines. 33 Indeed, T-type Ca 2ϩ channel blockade reportedly modulates autonomic activity. 34, 35 With that in mind, we hypothesized that in addition to its direct effects on cardiac electrophysiological properties, T-type Ca 2ϩ blockade reduces arrhythmogenicity by modulating autonomic nerve function. To test that idea, we used HRV as an index with which to evaluate cardiac autonomic function in WT and dnNRSF-Tg mice. 29 In mice, HRV predominantly correlates with parasympathetic activity. 36 Mice are nocturnal, so that for any given "day," the power in both the low-and high-frequency ranges was lower during the dark (night) phase, when the mice were more Values are meanϮSEM. Numbers of mice tested were as follows: Body weight, nϭ10 for each group; blood pressure, nϭ6 for WT mice, nϭ14 for dnNRSF-Tg mice without drugs, nϭ5 for dnNRSF-Tg mice treated with efonidipine, nϭ7 for dnNRSF-Tg mice treated with nitrendipine; echocardiographic data, nϭ4 for WT mice, nϭ5 for dnNRSF-Tg mice without drugs, nϭ6 for dnNRSF-Tg mice treated with efonidipine, nϭ5 for dnNRSF-Tg mice treated with nitrendipine; hemodynamic data, nϭ5 for WT mice, nϭ4 for dnNRSF-Tg mice without drugs, nϭ6 for dnNRSF-Tg mice treated with efonidipine, nϭ5 for dnNRSF-Tg mice treated with nitrendipine. *PϽ0.05 vs WT mice.
active, than during the light (day) phase (online-only Data Supplement Figure IA and IB). In dnNRSF-Tg mice, the incidences of both premature ventricular contractions and VTs were much greater during the dark phase, which suggests the involvement of autonomic nerve activity in the generation of arrhythmias in these mice (online-only Data Supplement Figure IC and ID). In addition, the averages of both the lowand high-frequency powers over 24 hours in dnNRSF-Tg mice were markedly lower than in WT mice, which indicates a general reduction in parasympathetic activity in dnNRSF-Tg mice ( Figure 4A , 4B, and 4C). Efonidipine dramatically increased the power in both the low-and high-frequency ranges of HRV in dnNRSF-Tg mice, whereas nitrendipine had little effect on HRV ( Figure 4A , 4B, and 4C). We also found that urinary excretion of norepinephrine, which is indicative of the level of sympathetic nerve activity, was significantly higher in dnNRSF-Tg than in WT mice ( Figure 5A ). Moreover, the increased excretion of norepinephrine seen in dnNRSF-Tg mice was attenuated significantly only by efonidipine ( Figure 5A ). We next evaluated the response of dnNRSF-Tg myocytes to catecholaminergic stimulation. We found that in the presence of isoproterenol 3 mol/L, isolated ventricular myocytes from dnNRSF-Tg hearts showed early afterdepolarizations and spontaneous action potentials, whereas myocytes from WT hearts did not ( Figure 5B, through 5D ). In addition, systemic administration of isoproterenol induced VT more frequently in dnNRSF-Tg mice than in WT mice ( Figure 5E ). These data support our idea that abnormal autonomic nervous system balance, with decreased parasympathetic activity and increased sympathetic activity, facilitates arrhythmogenesis in dnNRSF-Tg mice. The increase in the frequency of isoproterenol-induced VT seen in dnNRSF-Tg mice was attenuated significantly by efonidipine but not by nitrendipine ( Figure 5E ). Thus, along with its direct effect, which reduces the vulnerability of the heart to arrhythmogenic stress ( Figures 3D, 3E , and 5E), efonidipine also improves the cardiac autonomic nervous system balance, which further contributes to the suppression of lethal arrhythmias in dnNRSF-Tg mice.
R(؊)-Efonidipine, a Highly Selective T-Type Ca
2؉ Channel Blocker, Dramatically Improves Survival Among dnNRSF-Tg Mice
Recently, R(Ϫ)-efonidipine was shown to be a specific blocker of T-type Ca 2ϩ channels. 17, 18 To further confirm the 
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beneficial effects of T-type Ca 2ϩ channel blockade in the prevention of sudden death in dnNRSF-Tg mice, we administered R(Ϫ)-efonidipine (200 mg · kg Ϫ1 · d Ϫ1 PO) to dnNRSF-Tg mice for 20 weeks. We found that R(Ϫ)-efonidipine did not significantly affect blood pressure, heart rate, cardiac structure, or systolic function in either WT or dnNRSF-Tg mice compared with vehicle ( Figure 6A through   6E ). By contrast, R(Ϫ)-efonidipine dramatically improved the survival rate among dnNRSF-Tg mice, which clearly suggests that T-type Ca 2ϩ channel blockade prevents sudden death in dnNRSF-Tg mice ( Figure 6F ).
Efonidipine Reduces Sudden Death and Arrhythmogenicity in Mice With Acute Myocardial Infarction
Disturbance of cardiac autonomic nervous activity contributes to the incidence of arrhythmogenicity and mortality among patients with chronic heart failure due to nonischemic or ischemic cardiomyopathy, as well as among patients with acute myocardial infarction. 29 To test whether efonidipine can improve the survival rate among mice with a cardiomyopathy other than the nonischemic cardiomyopathy seen in dnNRSF-Tg mice, we administered efonidipine or nitrendipine to WT mice previously subjected to acute myocardial infarction. We found that efonidipine significantly reduced the incidence of sudden death during the subacute phase of myocardial infarction ( Figure 7A ), although blood pressure, cardiac systolic function, and cardiac structure were all similar in the control, efonidipine, and nitrendipine groups ( Figure 7B through 7F). When we further assessed arrhythmogenicity among these mice, we found that control mice with myocardial infarction were highly susceptible to induction of VT and that efonidipine, but not nitrendipine, significantly reduced the frequency of induced VT among mice with myocardial infarction ( Figure 7G ; online-only Data Supplement Figure II) .
Discussion
Ca 2ϩ influx is involved in multiple cellular processes, including cell growth, differentiation, and death. In cardiac myocytes, Ca 2ϩ influx plays important roles under both normal physiological and pathophysiological conditions. One of the major sources of Ca 2ϩ influx in excitable cells is voltagegated Ca 2ϩ channels, which have been classified into several types: L (long lasting), T (transient), N (neuronal), P/Q (Purkinje), and R (residual-drug resistant). Generally, cardiac myocytes express only the L and T types. 37 L-type Ca 2ϩ channels predominate in mature cardiac myocytes and are crucially involved in excitation-contraction coupling. 37 T-type Ca 2ϩ channels are expressed abundantly in embryonic ventricular myocytes. 4, 5 After birth, however, expression of T-type Ca 2ϩ channels is downregulated in ventricular myocytes, 4 ,5 so that they are restricted to the conduction system, 3, 5 where they modulate pacemaking activities. 3, 38 But under conditions of cardiac hypertrophy and heart failure, T-type Ca 2ϩ channels are reexpressed in ventricular myocytes, 4 . Two-way ANOVA revealed that Tg mice showed decreased blood pressure and enlarged LVDd compared with WT, and R(Ϫ) had no effect on blood pressure, heart rate, or echocardiographic data. 
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and they are thought to be involved in the altered cardiac function and arrhythmogenicity seen in the diseased myocardium. 2, 3 Consistent with that idea, the dual T-and L-type Ca 2ϩ channel blocker mibefradil attenuates the pathological processes seen in some animal models of cardiac disease. 10, 11, 39 Moreover, it was recently reported that genetic deletion of CACNA1H results in resistance to pathological cardiac hypertrophy. 9 Nonetheless, the effect of T-type Ca 2ϩ channel blockade on the incidence of malignant arrhythmias and sudden death remains unknown.
In the present study, we demonstrated that the dual T-and L-type Ca 2ϩ channel blocker efonidipine prevents the sudden death and arrhythmogenicity otherwise seen in dnNRSF-Tg mice, whereas nitrendipine, a selective L-type Ca 2ϩ channel blocker, does not. Suppression of arrhythmogenicity also was observed when dnNRSF-Tg mice were treated with mibefradil. Although the doses of nitrendipine used in the present studies (20 and 60 mg/kg) did not significantly affect blood pressure in dnNRSF-Tg mice, those doses previously were shown to effectively block L-type Ca 2ϩ channels in mice. 19 We also observed that treatment of db/db mice, a mouse model of type 2 diabetes-associated hypertension, 40 with nitrendipine 10 mg · kg Ϫ1 · d Ϫ1 for 8 days significantly reduced their elevated blood pressure (unpublished observation). These results clearly demonstrate that blockade of T-type Ca 2ϩ channels, not L-type Ca 2ϩ channels, mediates the effects of efonidipine and mibefradil on dnNRSF-Tg mice, although there is still the possibility that unknown effects of efonidipine and mibefradil on other currents are responsible. Furthermore, R(Ϫ)-efonidipine, a recently identified specific blocker of T-type Ca 2ϩ channels, 17, 18 dramatically improved the survival rate among dnNRSF-Tg mice, which strongly supports the notion that T-type Ca 2ϩ channels play a key role in mediating the lethal arrhythmias seen in this animal model. In addition, efonidipine, but not nitrendipine, also reduced the incidence of sudden death and arrhythmias among mice with acute myocardial infarction. Collectively, the lines of evidence summarized above demonstrate that T-type Ca 2ϩ channel blockade prevents sudden death and malignant arrhythmias in mice with heart failure caused by either nonischemic or ischemic myocardial injury.
Abnormalities in atrial and ventricular electrophysiology are well-recognized contributors to arrhythmogenesis in diseased human hearts. 1 In dnNRSF-Tg mice, the action potential is prolonged, and the resting membrane potential is depolarized, which is consistent with features observed in failing human hearts. 1 Notably, efonidipine significantly restored the resting membrane potential in ventricular myocytes from dnNRSF-Tg mice. Given that membrane depolarization can enhance arrhythmogenicity by inducing triggered activity mediated by early afterdepolarizations or delayed afterdepolarizations and by increasing automaticity, 1 restoration of the resting membrane potential is likely 1 of the mechanisms by which efonidipine prevents ventricular arrhythmias and sudden cardiac death in dnNRSF-Tg mice. Although we still do not fully understand the mechanism by which T-type Ca 2ϩ channel blockade restores the membrane potential in dnNRSF-Tg cardiomyocytes, the activation and availability of I Ca,T overlap at membrane potentials in the range of Ϫ60 to Ϫ30 mV, which could contribute to a pathological Ca 2ϩ leak into cells during diastole. 3 It was recently reported that elevation of diastolic Ca 2ϩ reduced the amplitude of I K1 , which is a critical determinant of resting membrane potential in ventricular myocytes. 41 In fact, the amplitude of I K1 was reduced significantly in dnNRSF-Tg ventricular myocytes (unpublished observation). It was also recently shown with mice lacking CACNA1H that the ␣1H T-type Ca 2ϩ channel plays a pivotal role in the induction of pathological calcineurin/nuclear factor-activated T cell signaling, which increases susceptibility to arrhythmias. 9, 42, 43 T-type Ca 2ϩ channel blockade may correct abnormalities in ventricular electrophysiology in part by inhibiting these pathological signaling pathways.
Disturbance of cardiac autonomic nervous activity that leads to increased sympathetic nerve activity and decreased parasympathetic nerve activity contributes to the increased arrhythmogenicity seen in patients with chronic heart failure. 44 HRV analysis is widely used to assess autonomic nerve function in the heart and has been shown to correlate with the prognosis of patients with heart failure. 31, 32 In the present study, efonidipine clearly reversed the altered HRV seen in dnNRSF-Tg mice. L-type Ca 2ϩ channel blockers generally enhance sympathetic nerve activity and reduce parasympathetic nerve activity. 34, 45 By contrast, efonidipine appears to have the opposite effects on autonomic nerve activity. In a previous study performed in mildly to moderately hypertensive patients, mibefradil enhanced parasympathetic nervous activity. 34 Similarly, in another study of hypertensive patients, efonidipine improved the disturbed balance in autonomic nerve activity in the heart. 35 The involvement of T-type Ca 2ϩ channels in the release of neurotransmitters, including catecholamines, from neuronal and endocrine cells may account for the effects of T-type Ca 2ϩ channel blockade on autonomic nerve activity. 33 Consistent with that idea, we observed in the present study that efonidipine significantly reduces the increase in urinary norepinephrine excretion otherwise seen in dnNRSF-Tg mice. Thus, along with its direct effects on the electrophysiology of ventricular myocytes, the effects of efonidipine on cardiac autonomic function likely contribute to the prevention of malignant arrhythmias and sudden death in dnNRSF-Tg mice. There is also the possibility that correcting the balance between sympathetic and parasympathetic nerve activity affects the electrophysiological properties of ventricular myocytes. The present results showing that efonidipine reduces the incidence of sudden death among mice with acute myocardial infarction further support the idea that correcting the balance in cardiac autonomic nerve activity through blockade of T-type Ca 2ϩ channels contributes to the prevention of malignant arrhythmias and sudden death by efonidipine, because disturbances in cardiac autonomic nervous activity are associated with sudden death in patients with acute myocardial infarction. 46, 47 Mibefradil was approved for use in the treatment of hypertension, angina pectoris, and congestive heart failure in 1997 but was withdrawn from the market because of an unexpected side effect unrelated to the T-type Ca 2ϩ channel blockade: It inhibited cytochrome p450s, thereby causing negative drug-drug interactions. 2 On the other hand, efonidip-ine has been used to treat hypertension for several years in Japan, and no such severe side effects have yet been identified. Although further investigation is necessary, we suggest that efonidipine or some other T-type Ca 2ϩ channel blockers, including the R(Ϫ)-isomer efonidipine, may be clinically useful for the prevention of sudden arrhythmic death in patients with heart failure.
